Michael J Boedigheimer

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Mixture modeling approach to flow cytometry data
    Michael J Boedigheimer
    Computational Biology, Amgen, Thousand Oaks, California, USA
    Cytometry A 73:421-9. 2008
  2. ncbi Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models
    Michael J Boedigheimer
    Amgen Inc, Thousand Oaks, CA 91320, USA
    Neoplasia 15:125-32. 2013
  3. ncbi Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
    Michael J Boedigheimer
    CDER, US FDA, Silver Spring, MD 20993, USA
    BMC Genomics 9:285. 2008

Detail Information

Publications3

  1. ncbi Mixture modeling approach to flow cytometry data
    Michael J Boedigheimer
    Computational Biology, Amgen, Thousand Oaks, California, USA
    Cytometry A 73:421-9. 2008
    ..Such alternative approaches can remove subjectivity in data analysis, improve efficiency and may ultimately enable construction of large bioinformatics data systems for more sophisticated approaches to hypothesis testing...
  2. ncbi Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models
    Michael J Boedigheimer
    Amgen Inc, Thousand Oaks, CA 91320, USA
    Neoplasia 15:125-32. 2013
    ..We sought to identify a gene array profile that could predict responsiveness to panitumumab, a fully human EGFR-binding antibody, using preclinical models of human cancer...
  3. ncbi Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
    Michael J Boedigheimer
    CDER, US FDA, Silver Spring, MD 20993, USA
    BMC Genomics 9:285. 2008
    ....